The following consensus is up to date for Dr. Martens as at 17 May 2024

Year ending
March 2023

Year ending
March 2024
Year ending
March 2025
Year ending
March 2026
Revenue (£m) £1,000.3 £888.3 £847.7 £900.0
EBITDA (£m) £245.0 £196.8 £145.4 £183.6
PBT* (£m) £159.4 £96.4 £40.2 £72.6
EPS 12.9p 7.1p 3.1p 5.6p
DPS 5.8p 4.2p 2.4p 3.0p

The above consensus is the mean average of forecasts gathered from 8 out of 8 covering sell-side analysts

*For FY24E to FY26E, adjusted PBT excludes foreign exchange gains/(losses)

Legal disclaimer

These financial forecasts are not prepared nor endorsed by Dr. Martens in any way. Dr. Martens has no current or pending duty to verify any individual estimates and assumes no responsibility to update, revise or otherwise comment on any of the information contained in these forecasts. It should be noted that financial forecasts are, by definition, forward looking, and are therefore subject to various risks and uncertainties which are subject to change at any time.